GLP-1R agonist therapy for diabetes: Benefits and potential risks

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 2, 2013, Pages 87-97

  Samson, Susan L ^a   Garber, Alan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular; GLP 1 receptor agonist; Glycemic control; Hypoglycemia; Safety

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; CAUSAL ATTRIBUTION; CLINICAL TRIAL; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE REACTION; KINESIOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; REVIEW; RISK BENEFIT ANALYSIS; THYROID CANCER;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN; MALE; PANCREATITIS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; THYROID NEOPLASMS; TREATMENT OUTCOME; VENOMS;

EID: 84874948153     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835edb32     Document Type: Review

References (61)

1. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24:1076-1082.
2. Brown JC, Dryburgh JR, Ross SA, Dupré J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 1975; 31:487-532.
3. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; ii:1300-1304.
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705.
5. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5149-5158.
6. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965.
7. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215.
8. Forst T, Weber MM, Pfützner A. Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res 2012; 2012:635472.
9. Byetta (exenatide BID) US prescribing information 2012. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021773s9s11s18s 22s25lbl.pdf.
10. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268:19650-19655.
11. Deyoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13:1145-1154.
12. Victoza (liraglutide) US prescribing information 2012. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022341s007s009s 013lbl.pdf.
13. Macconell L, Malloy J, Huang W, et al. Safety and efficacy of once monthly exenatide administration over 20 weeks in patients with type 2 diabetes. Diabetologia 2011; 54 (Suppl. 1):S38. [abstract 76].
14. Luskey K, Rosenstock J, Alessi T, Henry RR. Long-term, injection-free treatment with ITCA 650, a continuous subcutaneous delivery of exenatide via DUROS1device, leads to stable glycaemic and weight control for 48 weeks in metformin-treated type 2 diabetes. Diabetologia 2011; 54 (Suppl. 1):S39. [abstract 77].
15. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:4810-4817.
16. Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the onceweekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012; 29:1260-1267.
17. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the oncedaily GLP-1 receptor agonist lixisenatide in monotherapy. Diabetes Care 2012; 35:1225-1231.
18. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12:503-513.
19. Ratner RE, Rosenstock J, Boka G, DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010; 27:1024-1032.
20. Nauck MA, Petrie JR, Sesti G, et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. Diabetologia 2012; 55 (Suppl. 1):S7. [abstract 2].
21. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124:S3-S18.
22. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35:252-258.
23. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012; 35:683-689.
24. Garber AJ, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13:348-356.
25. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.
26. Buse JB, Nauck MA, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381:117-124.
27. Marre M, Penfornis A. GLP-1 receptor agonists today. Diabetes Res Clin Pract 2011; 93:317-327.
28. Clinicaltrials.gov NCT01029886. Available at http://www.clinicaltrials. gov/ct2/show/results/NCT01029886?term=liraglutide+AND+exenatide&rank=1.
29. Pratley RE, Barnett A, Feinglos M, et al. Efficacy and safety of once-weekly (QW) albiglutide vs. once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: Harmony 7 trial. Diabetes 2012; 61 (Suppl. 1):A240. [abstract 945-P].
30. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13:703-710.
31. Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obesity Metab 2013; 15:3-14.
32. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials. J Clin Endocrinol Metab 2011; 96:1695-1702.
33. DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets. Diabetes Care 2012; 35:1446-1454.
34. Rosenstock J, Ahren B, Chow F, et al. Once-weekly GLP-1R agonist albiglutide vs. titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (t2d) uncontrolled on glargine plus oral agents: similar glycemic control with weight loss and less hypoglycemia. Diabetes 2012; 61 (Suppl. 1):A15. [abstract 55-OR].
35. Seino Y, Min K, Niemoeller E, Takami A. Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin-SU. Diabetes 2011; 60 (Suppl. 1):A76. [abstract 278-OR].
36. Pratley RE, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65:397-407.
37. Montanya E, Pratley R, Nauck M, et al. Switching from sitagliptin to liraglutide, in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes. Diabetes 2011; 60 (Suppl. 1):A307. [abstract 1118-P].
38. Peyrot M, Rubin RR. How does treatment satisfaction work? Modeling determinants of treatment satisfaction and preference. Diabetes Care 2009; 32:1411-1417.
39. Davies M, Pratley R, Hammer M, et al. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as add-on to metformin. Diabetic Med 2011; 28:333-337.
40. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14:882-892.
41. Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharm 2012; 13:1451-1467.
42. Bydureon (exenatide QW) US prescribing information 2012. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022200Orig 1s000lbledt.pdf.
43. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. Diabetes Care 2010; 33:2349-2354.
44. Pendergrass M, Chen W. Association between diabetes, exenatide, sitagliptin and acute pancreatitis. Diabetes 2010; 59 (Suppl. 1):A160. [abstract 587-P].
45. Wenten M, Gaebler J, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other antidiabetic medication: a follow-up study. Diabet Med 2012; 29:1412-1418.
46. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13:559-566.
47. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32:834-838.
48. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141:150-156.
49. EASD commentary 2011. Available at http://87.234.226.93/easd-intranet/ easdwebfiles/statements/Elashoff-Commentary.pdf.
50. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151:1473-1486.
51. Hegedüs L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011; 96:853-860.
52. FDA. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInfor mation/Guidances/ucm071627.pdf.
53. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8:237-240.
54. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10:22.
55. Linnebjerg H, Seger M, Kothare P, et al. The effect of exenatide on QTc interval in healthy subjects. Diabetes 2009; 58 (Suppl. 1):A161. [abstract 597-P].
56. Sager P, DarpöB, Han J, et al. Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes. Diabetes 2011; 60 (Suppl. 1): A294. [abstract 1070-P].
57. Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009; 11:1353-1362.
58. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - a long term evaluation (LEADER®). Available at http://www.clinical trials.gov/ct2/show/NCT01179048?term=NCT01179048&rank=1.
59. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available at http://www.clinical trials.gov/ct2/show/NCT01144338?term=NCT01144338&rank=1.
60. Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA). Available at http://www.clinicaltrials.gov/ct2/show/NCT01147250?term= NCT01147250&rank=1.
61. Researching Cardiovascular Events With a Weekly Incretin in Dia betes (REWIND). Available at http://www.clinicaltrials.gov/ct2/show/NCT01394952?term= NCT01394952&rank=1.